Your institution may have access to this item. Find your institution then sign in to continue.
Title
An Inhaled Insulin (Afrezza)
Abstract
A reprint is presented of an article which appeared in the March 2, 2015, issue of "The Medical Letter on Drugs and Therapeutics" on Afrezza, an inhaled form of rapid-acting insulin from pharmaceutical companies Mannkind and Sanofi for use by patients with type 1 or type 2 diabetes which has recently been approved the U.S. Food and Drug Administration. Topics include its pharmacokinetics, possible adverse effects, and dosing.